May 9th 2024
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Novel Agent Shows Benefit Combined with Nivolumab in Microsatellite Stable CRC
December 20th 2018Novel immunomodulatory agent pixatimod combined with nivolumab, a PD-1 inhibitor, may benefit patients with advanced bowel cancers, including a small subset of those with colorectal cancer considered to be microsatellite stable.
Read More
Every Patient With a GI Tumor Should Have MSI Testing Done, Saif Says
December 14th 2018Wasif Saif, MD, MBBS, recently talked about the treatment considerations and decisions he makes when treating patients with colorectal cancer. Saif explained his treatment decisions based on a case scenario during a <em>Targeted Oncology</em> live case-based peer perspectives presentation.
Read More
Keiser Compares the Use of 2 Agents for Patients With Metastatic CRC
December 14th 2018During a <em>Targeted Oncology </em>live case-based peer perspectives presentation, L. Wayne Keiser, MD, talked about the treatment considerations and decisions he makes when treating patients with colorectal cancer. Keiser, a medical oncologist at St. Joseph Health Medical Group, Santa Rosa, California, explained his treatment decisions for the based on a case scenario of a patient with <em>KRAS</em>-mutated metastatic CRC.
Read More
Trial Investigators Discuss FDA Draft Guidance on Master Protocols
December 1st 2018Complex drug trials that use a single protocol to test either 1 agent against multiple cancers or multiple agents against 1 cancer can make drug testing faster, cheaper, and more informative, particularly when those trials use the data to constantly improve protocols.
Read More
Greenwald Celebrates Successes in National Colorectal Cancer Screening Campaign
November 29th 2018The National Colorectal Cancer Roundtable may have come up short in its goal to get 80% of American adults ≥50 years screened for colorectal cancer by 2018, but David A. Greenwald, MD, told his audience at the 2018 American College of Gastroenterology Annual Meeting that the group can point to smaller victories that deserve recognition.
Read More
Neoadjuvant Nivolumab/Ipilimumab Combination Shows Activity in Early-Stage dMMR Colon Cancer
November 14th 2018According to findings from the first neoadjuvant study to test ipilimumab (Yervoy) plus nivolumab (Opdivo) in early-stage mismatch repair deficient tumors and MMR proficient colon cancers, the combination induced major pathologic responses from all 7 patients with dMMR tumors.
Read More
Immunoscore Provides Risk Assessments for All Stages of Colon Cancer
November 13th 2018In a presentation at the 33<sup>rd</sup> Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cance, Dr. Galon discussed the definition of the immune contexture of Immunoscore, its international validation for the risk-classification of stage I-III colon cancer, and the potential value of Immunoscore in stage IV metastatic disease.
Read More
Two Rapid-Fire Abstracts Break Down Biomarkers of Response and Resistance
November 12th 2018An analysis of immunologic biomarkers in a phase II trial of patients with advanced colorectal cancer treated with chemotherapy and PD-1 checkpoint inhibition identified several factors associated with a patient’s beneficial response to the chemo-immunotherapy regimen, according to findings presented during the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.
Read More
Expert Discusses Real-World Dosing Findings With Regorafenib in mCRC
November 7th 2018Considering data from the real-world setting is becoming increasingly important with the use of anticancer agents, as there is likely a big difference between patients in a clinical trial and patients in the real world, said Juan Manuel O’Connor, MD. During the 2018 ESMO Congress, O'Connor presented real-world dosing findings for regorafenib in patients with metastatic colorectal cancer.
Read More